ARK Genomic Revolution ETF (ARKG)
| Assets | $7.60B |
| NAV | $78.65 |
| Expense Ratio | 0.75% |
| PE Ratio | n/a |
| Shares Out | 96.66M |
| Dividend (ttm) | $0.79 |
| Dividend Yield | 1.00% |
| Ex-Dividend Date | Dec 29, 2020 |
| 1-Year Return | - |
| Volume | 2,380,215 |
| Open | 78.52 |
| Previous Close | 78.65 |
| Day's Range | 76.64 - 78.65 |
| 52-Week Low | 62.29 |
| 52-Week High | 115.15 |
| Beta | 1.57 |
| Holdings | 57 |
| Inception Date | Oct 31, 2014 |
About ARKG
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
Top 10 Holdings
41.89% of assets| Name | Symbol | Weight |
|---|---|---|
| Teladoc Health | TDOC | 6.99% |
| Exact Sciences | EXAS | 5.01% |
| Pacific Biosciences of California | PACB | 4.61% |
| Vertex Pharmaceuticals | VRTX | 4.16% |
| Fate Therapeutics | FATE | 4.12% |
| Ionis Pharmaceuticals | IONS | 4.08% |
| Regeneron Pharmaceuticals | REGN | 3.62% |
| Twist Bioscience | TWST | 3.30% |
| Takeda Pharmaceutical | TAK | 3.02% |
| Accolade | ACCD | 2.98% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2020 | $0.42557 | Dec 31, 2020 |
| Dec 27, 2019 | $1.05395 | Dec 31, 2019 |
| Dec 27, 2018 | $0.26999 | Dec 31, 2018 |
| Dec 27, 2017 | $0.19272 | Dec 29, 2017 |
| Dec 28, 2016 | $0.00 | Jan 4, 2017 |
| Dec 24, 2015 | $0.00 | Dec 31, 2015 |
News
Gilded Age of Genomics Just Getting Started
Genomics is one of the cornerstones of disruptive growth in the healthcare sector. Relevant to investors is that genomics is still in its nascent stages, indicating that there's a potentially lengthy ru...
Google Getting Into Genomics? It Already Is
Google parent Alphabet (NASDAQ:GOOG) has a long history of disruption and one that extends far beyond internet search and advertising. As such, it's not surprising that the stock makes appearances in ex...
Early Cancer Detection: Major Opportunity for Genomics Investors
Genomics is one of the epicenters of futuristic healthcare investing, and the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is one of the top exchange traded funds for accessing that theme. Addi...
Genomics Could Again Be Prime Time Idea
As experienced investors know, it takes some patience to engage with genomics stocks. That's just the lay of the land with one of the more volatile, yet promising, growth-rich corners of the healthcare ...
The next breakthroughs in biotech
Ali Urman, Ark Invest genomics analyst, joins Fast Money 'The Next,' to discuss future of biotech.
Cathie Wood's ARK Invest Buys Over 150,000 Shares of This COVID-19 Vaccine Supplier
One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 150,000 shares of Pfizer Inc.
ARK ETF Investors Not Getting Seasick
In spite of rocky performance in 2021, investors are still betting on ARK Funds' bright future.
Cathie Wood's ARK Invest Buys Over 1.3 Million Shares of This Health Information Company
One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 1.3 million shares of Sema4 Holdings Corp.
Cathie Wood's ARK Invest Buys Over 7 Million Shares of This Biotech-Focused SPAC
A couple ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 7 million shares of Soaring Eagle Acquisition Corp.
Cathie Wood's ARK Invest Doubles Down on Buying This Biotech-Focused SPAC
One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought nearly 2 million shares of Soaring Eagle Acquisition Corp.
Cathie Wood's ARK Invest Buys Over 4.1 Million Shares of This Biotech-Focused SPAC
One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 4.1 million shares of Soaring Eagle Acquisition Corp.
Genomics Advancements Could Aid Breast Cancer Prevention
One of the primary objectives of genomics is to make strides in areas where traditional healthcare procedures and techniques have failed or aren't generating enough in the way of advancements and improv...
Cathie Wood's ARK Invest Buys Over 850,000 Shares of Pacific Bio
A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 850,000 shares of Pacific Biosciences of California Inc.
Q2 Growth 'Nothing Short Of Virtuous': Economist
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn't be so pessimistic.
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner.
Unpacking the Potential of the Synthetic Biology Space
As an actively managed exchange traded fund, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) can more nimbly move into new healthcare frontiers than rival index-based products. Synthetic biolo...
Tech Bubble 2.0 + Inflation Tsunami: How to Play Them Now
Morgan Stanley warns investors 15% correction coming as market overvalued like dot-com days.
How Healthcare ETFs Can Get Their Swagger Back
With mergers and acquisitions activity yet to heat up, healthcare stocks are lagging the broader market to this point in 2021. The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) hasn't been immun...
The ARKG ETF and the Intersection of All Things Tech
It's often said that disruptive technologies frequently intersect with each other. For example, cloud computing and the Internet of Things (IoT) are frequently linked to advancements in cybersecurity.
Where Will ARK Genomic Revolution ETF Be in 5 Years?
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."